Diabetic nephropathy is kidney damage caused by diabetes. High blood sugar over time damages the small blood vessels in the kidneys, reducing their ability to filter waste. It is one of the leading causes of kidney failure. Treatment focuses on blood sugar control, blood pressure management, and medications that protect the kidneys — including a newer class of diabetes drugs that have shown significant kidney-protective effects.
What's actually going on in research
Trials are testing new combinations of drugs that attack kidney damage through multiple pathways, drugs originally developed for heart disease that also protect the kidneys, anti-inflammatory treatments targeting the immune response in kidney tissue, and gene therapies in early testing. The goal is to slow progression or halt it before dialysis becomes necessary.
SGLT2 inhibitor combinations
A class of diabetes drugs called SGLT2 inhibitors has been shown to protect the kidneys well beyond their effect on blood sugar. Trials are testing them in combination with other kidney-protective drugs and in patients with more advanced kidney disease who were previously excluded.
Finerenone and mineralocorticoid blockers
A newer type of drug that blocks a hormone pathway driving kidney inflammation is being tested alongside standard care. Trials are exploring whether the combination slows kidney decline faster than either drug alone.
Anti-inflammatory approaches
Kidney damage in diabetes involves chronic inflammation and immune activation. Trials are testing targeted anti-inflammatory drugs — some borrowed from autoimmune disease research — to interrupt this process.
What to know before you search
Eligibility typically depends on how much kidney function remains (measured by eGFR), protein in the urine, blood sugar levels, type of diabetes, current medications, and whether other kidney or heart conditions are present.
What types of trials are currently open
- Drug combination trials — Testing whether combining two or more kidney-protective medications works better than any single drug, often building on established drugs with new additions.
- SGLT2 inhibitor trials — Testing this class of diabetes drugs in populations not yet included in earlier studies — including people with more advanced kidney disease or those without diabetes.
- Anti-inflammatory trials — Testing drugs that reduce inflammation in kidney tissue, targeting the immune pathways activated by high blood sugar.
- Blood pressure and fluid management trials — Testing specific blood pressure targets or drug combinations to find the best way to protect kidneys while avoiding side effects.
- Biomarker and monitoring trials — Testing whether specific blood or urine markers can predict who will progress to kidney failure faster, helping target intensive treatment to those who need it most.
Recently added Diabetic Nephropathy trials
Receive a stem cell injection to help repair kidney damage
Diabetic nephropathy (DN) is one of the most significant microvascular complications of diabetes mellitus. Its incidence can reach 30%-40% after 20 years of diabetes duration, among which 5%-10% of patients will progress to end-stage renal disease, where renal function is essentially lost, and only hemodialysis or kidney transplantation can sustain or save lives. Given the current lack of effective clinical measures for treating diabetic nephropathy, exploring new strategies for its prevention and treatment is of great significance. Diabetic nephropathy is caused by persistent hyperglycemia, and its key pathological features include chronic inflammatory cell infiltration in kidney tissue, podocyte apoptosis in the glomeruli, pyroptosis of renal tubular epithelial cells, and renal fibrosis. Therefore, the key to treating diabetic nephropathy lies in inhibiting chronic renal inflammation and alleviating the resulting tissue and cell damage; reducing glomerular podocyte apoptosis and renal tubular epithelial cell pyroptosis, lowering proteinuria levels, and delaying the pathological progression of diabetic nephropathy; suppressing renal fibrosis; and regenerating new renal tissue cells to partially restore renal tissue structure and function. Current clinical treatments for diabetic nephropathy primarily involve strict glycemic control and the use of angiotensin-converting enzyme inhibitors or angiotensin II receptor antagonists. Numerous clinical studies have shown that these therapeutic measures can only partially delay the onset and slow the progression of diabetic nephropathy, but cannot reverse renal damage. Accumulating evidence indicates that mesenchymal stem cells (MSCs) can migrate and home to injured kidney tissues, directionally differentiate into renal parenchymal cells to repair and regenerate damaged tissue cells; secrete nutritional factors to improve local blood supply and the microenvironment of renal tissue; and release anti-inflammatory and immunomodulatory factors, exerting potent anti-inflammatory and immunomodulatory effects, thereby reducing inflammatory injury and apoptosis of renal tissue cells and alleviating renal fibrosis. Therefore, mesenchymal stem cells have emerged as a new hope for the treatment of diabetic nephropathy.
QUARTET-DKD: Quadruple Therapy for Type 2 Diabetic Nephropathy
This study employs a prospective, randomized, double-blind, parallel-controlled design, aiming to enroll adult participants with type 2 diabetic kidney disease (DKD) who meet the eligibility criteria. With an angiotensin receptor blocker (ARB) as the background therapy, all participants will be randomized in a 1:1:1:1 ratio into four treatment groups: Group 1 (G1): ARB + empagliflozin + finerenone placebo + mazdutide placebo; Group 2 (G2): ARB + empagliflozin + finerenone + mazdutide placebo; Group 3 (G3): ARB + empagliflozin + mazdutide + finerenone placebo; Group 4 (G4): ARB + empagliflozin + mazdutide + finerenone. The primary comparisons include G2 vs. G1, G3 vs. G1, G4 vs. G2, and G4 vs. G3, designed to evaluate the superiority of triple therapy over dual therapy, and quadruple therapy over triple therapy, in reducing the urine albumin-to-creatinine ratio (UACR).
Find Diabetic Nephropathy trials matched specifically to you
Answer 3 quick questions and we'll show you trials that fit your situation.